Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234297 · ClinicalTrials.gov registry record · Phase 1
Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery
A Phase 1 study of Glioma, sponsored by Blaze Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT02234297: Completed Phase 1 study of Glioma, sponsored by Blaze Bioscience.
NCT02234297 is a Phase 1 study of Glioma that has completed, run by Blaze Bioscience. The registered enrollment target is 17 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02234297, a Phase 1 study of Glioma, has completed, sponsored by Blaze Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. We hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as operate. This is a safety study to assess the safety of BLZ-100 in patients with gliomas undergoing surgery.
Primary Outcome
Safety will be assessed by physical examination and measurement of vital signs and laboratory safety parameters.
Conditions Studied
Interventions
- DRUG BLZ-100
Study Locations (2)
California
- Cedars-Sinai Medical Center - Los Angeles
Queensland
- NEWRO Foundation - Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
What the finished NCT02234297 record still lists
NCT02234297 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which BLZ-100 is the first listed.
NCT02234297 reports a single indexed study location in California, Queensland.
Frequently Asked Questions
What is clinical trial NCT02234297 about?
NCT02234297 is a clinical study titled "Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery". Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor...
What is the current status of trial NCT02234297?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2014-10. Estimated completion is 2016-03.
What conditions does trial NCT02234297 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT02234297?
The interventions under investigation include: BLZ-100 (DRUG).
Who is sponsoring clinical trial NCT02234297?
This trial is sponsored by Blaze Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02234297 being conducted?
This trial has 2 study locations across California, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02234297's enrollment target sits among peer trials
17 75th of 87 higher than 13 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia